2026年02月03日，冰轮环境披露接待调研公告，公司于02月03日接待睿远基金、东方证券自营、财通证 券、银河证券、申万证券等9家机构调研。 调研情况显示，冰轮环境致力于在能源和动力领域提供先进的系统解决方案和全生命周期服务，主要产 品形式为压缩机和换热装置，实施温控、增压等冷热能管理功能，覆盖-271℃-200℃温度区间。具体产 品包括螺杆式压缩机、离心式压缩机、吸收式制冷机、活塞式压缩机、涡旋式压缩机、工业热泵、储能 蓄能装置、真空冻干设备、速冻装置、换热设备、船用制冷设备、多联机等，广泛应用于商业制冷系 统、工业冷冻系统、商用舒适空调、工业特种空调等多个领域。 公司在数据中心液冷系统应用方面，旗下顿汉布什公司和冰轮换热技术公司为数据中心乃至液冷系统提 供一次侧冷源装备和热交换装置等冷却装备。顿汉布什公司已有131年历史，其"变频离心式冷水机 组"和"集成自然冷却功能的风冷螺杆冷水机组"两项产品入选工信部《国家绿色数据中心先进适用技术 产品目录》，已成功服务国家超级计算广州中心、中国移动贵州大数据中心等诸多项目。在核电领域， 公司聚焦核岛冷却、核能供热等核心场景，服务了红沿河、宁德、阳江等多个核电站，旗 ...

智通财经APP获悉，东方证券发布研报称，谷歌DeepMind开放世界模型Genie3的实验性研究原 型"Project Genie"，允许用户创建、编辑并探索虚拟世界。当前无需过度担忧海外Genie3等通用世界模 型，游戏商用潜力极低，即使是未来对于时长支持增长，Genie3判断可能仅能支持有限的剧情向游戏， 而无法很好支持无限时长延申的大型多人在线游戏。AI游戏编辑器开始兑现增长，拥有大DAU平台的 企业，尤其是能与自研AI引擎相结合的企业，有望获得未来AIGC游戏平台的入场券。 东方证券主要观点如下： 事项：北京时间2026年1月30日凌晨，谷歌DeepMind开放了世界模型Genie3的实验性研究原型"Project Genie"，允许用户创建、编辑并探索虚拟世界。同时在1月30日晚，心动公司、TapTap平台创始人黄一 孟在各大平台同步开启直播，正式官宣一款新产品"Taptap制造"。 国内AI游戏编辑器的技术路径已具备落地商用条件 以心动、腾讯为代表的国内厂商，其技术实现路径核心在于拆解游戏生产环节、AI模拟程序员的部分 生产工作，通过将AI输出的资产封装至通用硬编物理引擎，实现AI3D引擎能力与传 ...

Group 1 - A-shares brokerage stocks have shown strong performance, with Huayin Securities rising over 7% and Dongwu Securities increasing over 3% [1] - Other notable gainers include Huaxin Securities, Guotai Haitong, and Southwest Securities, each rising over 2% [1] Group 2 - Huayin Securities has a market capitalization of 51.7 billion and a year-to-date increase of 24.85% [2] - Dongwu Securities has a market capitalization of 47.3 billion and a year-to-date increase of 4.97% [2] - Huaxin Securities has a market capitalization of 18.1 billion and a year-to-date increase of 12.01% [2] - Guotai Haitong has a market capitalization of 352.4 billion but a year-to-date decrease of 2.73% [2] - Southwest Securities has a market capitalization of 30.4 billion and a year-to-date increase of 2.23% [2]

Core Viewpoint - The company is facing short-term performance pressure but is expected to drive innovation through self-research and transformation [1] Financial Performance - The company recently released a performance forecast for 2025, expecting a net loss attributable to shareholders of 66 million to 96 million yuan, and a non-recurring net loss of 79 million to 110 million yuan [1] - The performance pressure is primarily due to the impact of centralized procurement and the MAH system on the company's generic drug business [1] Strategic Initiatives - The company aims to optimize its business structure and return to a growth trajectory through active innovation [1] - A recent collaboration with Zhongshen Innovation on the self-researched oncology drug BIOS-0629 will provide the company with a milestone payment of 300 million yuan and a 10% share of the sales revenue [1] Long-term Outlook - Despite short-term performance challenges, the company's long-term development potential is considered significant [1] - The company’s insights into the industry and research capabilities are expected to lead to a second growth curve through innovative drug development and licensing [1] Earnings Forecast - The earnings per share (EPS) for 2025-2026 are projected to be -0.63 yuan and 0.37 yuan, respectively, down from previous estimates of 2.49 yuan and 2.80 yuan [1] - The EPS for 2027 is forecasted to be 0.61 yuan [1] Valuation - A DCF valuation method is employed, with a target price set at 53.84 yuan, maintaining a "buy" rating [1]

智通财经APP获悉，东方证券发布研报称，国内拟将铜精矿纳入国家战略储备体系，以应对75%高进口 依存度，增强产业链安全。全球铜矿品位下降及资本开支不足加剧供给紧张，而新能源等领域需求持续 增长，支撑铜价中期上行。中国严控铜冶炼新增产能，"反内卷"政策有望推动铜价与冶炼费同步上升， 利好相关企业利润修复。 东方证券主要观点如下： 铜冶炼"反内卷"政策不变，继续看好铜价与铜冶炼费齐升的中期趋势 除对铜资源储备体系建设的完善外，发布会上秘书长段绍甫表示已叫停200多万吨铜冶炼项目，未来将 继续配合国家有关部门严控新增矿铜冶炼项目，副会长陈学森也表示，当前铜"反内卷"政策正在出台， 效果预计在后续两三年内逐步体现。该行认为，在国内铜冶炼产能严控新增以及"反内卷"政策落地见效 的预期下，铜冶炼费在中期有望迎来向上修复。该行继续看好中期铜价与铜冶炼费齐升，关注铜矿企业 以及铜冶炼企业的利润修复空间和投资机会。 投资建议：铜矿端：建议关注资源储量较大、中期铜矿持续扩产存在增量预期的紫金矿业，其他标的： 洛阳钼业、金诚信。铜冶炼端：建议关注米拉多铜矿放量提升铜精矿自给率、现货冶炼费改善预期下利 润弹性更为受益的铜陵有色。其他 ...

Core Insights - The report from Dongfang Securities highlights the significant commercial value of extrahepatic delivery technology, driven by MNCs' increasing interest and the rapid development of domestic companies in multi-target drugs and extrahepatic delivery platforms [1][2][3] Group 1: Market Dynamics - Frequent transactions in small nucleic acids indicate rising global recognition of domestic drugs, exemplified by recent strategic collaborations involving Shengyin Biotech and major pharmaceutical companies like Eli Lilly and Roche, which include upfront payments and milestone payments totaling up to $12 billion and $15 billion respectively [1] - MNCs are shifting focus from liver-targeted delivery technologies to extrahepatic delivery systems, targeting organs such as fat, muscle, central nervous system, heart, and kidneys, which could address significant unmet clinical needs [2] Group 2: Domestic Innovation - Domestic companies have accumulated substantial experience in chemical modifications and liver-targeted delivery technologies for small nucleic acids, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [3] - The proactive development of extrahepatic delivery platforms and multi-target small nucleic acid drug platforms positions domestic firms at the forefront globally, attracting MNCs' interest [3] Group 3: Investment Opportunities - Potential investment targets include companies such as Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Chengdu Xian Dao, and others, which are positioned to benefit from the growing market for small nucleic acid drugs [4]

Group 1 - The core viewpoint of the articles highlights the strong performance expectations for listed securities firms in 2025, driven by a vibrant capital market and robust growth in brokerage and proprietary trading businesses [1][2] - As of January 30, 2025, 21 listed securities firms have disclosed their performance forecasts, with leading firms like CITIC Securities and Guotai Junan expected to maintain their market dominance, projecting CITIC Securities' net profit to exceed 30 billion yuan and Guotai Haitong's net profit growth rate to exceed 100% year-on-year [1] - Smaller securities firms are anticipated to show even greater profit elasticity, with Guolian Minsheng forecasting a year-on-year net profit growth rate exceeding 400% [1] Group 2 - The growth drivers for the 2025 performance of these listed securities firms include brokerage and proprietary trading businesses, supported by a favorable A-share market environment and government policies aimed at stabilizing growth and boosting the capital market [2] - Factors such as a moderately loose liquidity environment, continuous optimization of the capital market, and the restoration of investor confidence are expected to collectively enhance the performance of the securities sector [2] - The current valuation of the securities sector is at a historical low, presenting a defensive rebound opportunity, with recommendations to focus on strong leading firms and those with competitive advantages in wealth management, proprietary trading, and cross-border business [2]

Investment Rating - The report maintains an "Overweight" rating for the non-bank financial industry [1] Core Insights - The equity market is expected to perform well, with a projected net profit growth of 50% year-on-year for 2025, and a 16% growth in 2026 from a high base [1][30] - The average daily trading volume of stock funds is anticipated to reach 19.814 trillion yuan in 2025, representing a 67% year-on-year increase [1][9] - The report highlights a significant recovery in IPO and refinancing activities, with IPO fundraising expected to grow by 96% in 2025 [1][14] - The bond issuance scale is expected to increase steadily, with a 13% year-on-year growth in 2025 [1][19] - The report emphasizes the low valuation of brokerage stocks and the potential for valuation recovery, particularly for large brokerages [1][24] Summary by Sections 1. Equity Market Performance - The average daily trading volume of stock funds is projected at 19.814 trillion yuan, a 67% increase year-on-year [1][9] - The number of new accounts opened in the Shanghai market is expected to average 2.5 million per month, an 8% increase from 2024 [1][9] - The financing balance is projected to reach 2.5242 trillion yuan, a 36% increase year-on-year [1][12] - The IPO market is expected to see 116 IPOs raising 131.8 billion yuan, a 96% increase year-on-year [1][14] - The refinancing market is expected to recover significantly, with a total of 950.9 billion yuan raised, a 326% increase [1][18] 2. Profit Forecast for 2025 - The report forecasts a 50% year-on-year increase in net profit for listed brokerages in 2025, with a 16% increase in Q4 [1][30] - The total revenue for the industry is expected to grow by 21% year-on-year [1][30] 3. 2026 Outlook - The report anticipates a 16% year-on-year increase in net profit for the industry in 2026, based on high baseline assumptions [1][37] - The growth in brokerage income from various segments is expected, including a 25% increase in brokerage business revenue [1][37] 4. Valuation and Recommendations - The report notes that the current valuation of brokerages is relatively low, with the CITIC Securities II index at 1.43x PB, indicating potential for valuation recovery [1][24] - Key recommendations include major brokerages such as CITIC Securities, Huatai Securities, and Guotai Junan [1][24]

公司名稱: 東方證券股份有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600958 | 說明 | | 上海證券交易所 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 7,469,482,864 RMB | | 1 | RMB | | 7,469,482,864 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | | 7,469,482,864 RMB | | 1 | RMB | | 7,469,482,864 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東方證券股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600958 | 說明 | | 上海證券交易所 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 7,469,482,864 RMB | | 1 | RMB | | 7,469,482,864 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | | 7,469,482,864 RMB | | 1 | RMB | | 7,469,482,864 | | 2 ...